Summit Therapeutics (SMMT) stock gains as AstraZeneca (AZN) is said to eye its lung cancer drug ivonescimab, a potential ...

Bristol Myers’BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...

Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.

UBS reaffirmed its Buy rating and $105 target for Merck, brushing off investor pessimism about the pharmaceutical giant’s ...

AEMD READ THE FULL AEMD RESEARCH REPORT Assessing if the Hemopurifier in conjunction with standard of care treatment can increase the population that can benefit from combined treatment Aethlon ...